PMID- 22559254
OWN - NLM
STAT- MEDLINE
DCOM- 20130123
LR  - 20220310
IS  - 1557-8534 (Electronic)
IS  - 1547-3287 (Linking)
VI  - 21
IP  - 13
DP  - 2012 Sep 1
TI  - Haplotype-based banking of human pluripotent stem cells for transplantation: 
      potential and limitations.
PG  - 2364-73
LID - 10.1089/scd.2012.0088 [doi]
AB  - High expectations surround the area of stem cells therapeutics. However, the 
      cells' source-adult or embryonic-and the cells' origin-patient-derived autologous 
      or healthy donor genetically unrelated-remain subjects of debate. Autologous 
      origins have the advantage of a theoretical absence of immune rejection by the 
      recipient. However, this approach has several limitations with regard to the 
      disease of the recipient and to potential problems with the generation, 
      expansion, and manipulation of autologous induced pluripotent stem cells (iPS 
      cells) preparation. An alternative to using autologous cells is the establishment 
      of a bank of well-characterized adult cells that would be used to generate iPS 
      cells and their derivatives. In the context of transplantation, such cells would 
      come from genetically unrelated donors and the immune system of the recipient 
      would reject the graft without immunosuppressive therapy. To minimize the risk of 
      rejection, human leukocyte antigen (HLA) compatibility is certainly the best 
      option, and the establishment of an HLA-organized bank would mean having a 
      limited number of stem cells that would be sufficient for a large number of 
      recipients. The concept of haplobanking with HLA homozygous cell lines would also 
      limit the number of HLA mismatches, but such an approach will not necessarily be 
      less immunogenic in terms of selection criteria, because of the limited number of 
      HLA-compatible loci and the level of HLA typing resolution.
FAU - Zimmermann, Anna
AU  - Zimmermann A
AD  - Laboratory of Experimental Cell Therapy, Department of Genetic and Laboratory 
      Medicine, Geneva University Hospital and Medical School, Geneva, Switzerland.
FAU - Preynat-Seauve, Olivier
AU  - Preynat-Seauve O
FAU - Tiercy, Jean-Marie
AU  - Tiercy JM
FAU - Krause, Karl-Heinz
AU  - Krause KH
FAU - Villard, Jean
AU  - Villard J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120611
PL  - United States
TA  - Stem Cells Dev
JT  - Stem cells and development
JID - 101197107
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Cell Culture Techniques/methods
MH  - Embryo, Mammalian/cytology
MH  - Graft Rejection/immunology
MH  - HLA Antigens/immunology
MH  - *Haplotypes
MH  - Histocompatibility Testing/methods
MH  - Homozygote
MH  - Humans
MH  - Induced Pluripotent Stem Cells/immunology/physiology/*transplantation
MH  - Parthenogenesis
MH  - Stem Cell Research/ethics
MH  - Tissue Banks/ethics/*standards
MH  - Tissue Donors
EDAT- 2012/05/09 06:00
MHDA- 2013/01/24 06:00
CRDT- 2012/05/08 06:00
PHST- 2012/05/08 06:00 [entrez]
PHST- 2012/05/09 06:00 [pubmed]
PHST- 2013/01/24 06:00 [medline]
AID - 10.1089/scd.2012.0088 [doi]
PST - ppublish
SO  - Stem Cells Dev. 2012 Sep 1;21(13):2364-73. doi: 10.1089/scd.2012.0088. Epub 2012 
      Jun 11.